RBC Downgrades ResMed, Cuts Price Target on Cautious Outlook

Key Facts

In a move reflecting a shift toward a more conservative stance within the healthcare sector, RBC has downgraded ResMed (RMD) from Outperform to Sector Perform. This adjustment comes as analysts significantly reduced the stock's price target from $276 to $234. According to reports, the decision reflects a neutral outlook on the company's growth prospects and a more cautious valuation of its market position moving forward.

The downgrade occurs as ResMed faces evolving competition in the sleep apnea device market, particularly as investors weigh the long-term impact of GLP-1 medications on device demand. Per market data, major peer Philips continues to navigate recovery from extensive product recalls, which previously allowed ResMed to capture significant market share; however, RBC suggests these tailwinds may now be fully priced into the stock.

Regarding market performance, RMD stood at $202.76 at the close of July 16, 2026, remaining well below the newly established target. Traders are currently looking toward broader macro catalysts, such as the U.S. Monetary Policy Report on July 10, 2026, which could influence financing costs for medical technology growth stocks, while awaiting further company-specific operational updates.